Ixchiq (VLA1553): The first FDA-approved vaccine to prevent disease caused by Chikungunya virus infection
Author:
Top Cited Papers
Open Access
- 13 January 2024
- journal article
- editorial
- Published by Taylor & Francis in Virulence
- Vol. 15 (1) , 2301573
Abstract
No abstract availableKeywords
Funding Information
- no funding associated with the work featured in this article
This publication has 6 references indexed in Scilit:
- Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in neednpj Vaccines, 2023
- Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2023
- Chikungunya vaccines: An update in 2023Asian Pacific Journal of Allergy and Immunology, 2023
- Chikungunya Virus: Pathophysiology, Mechanism, and ModelingViruses, 2017
- Chikungunya virus: host pathogen interactionReviews in Medical Virology, 2011
- Chikungunya Fever: An Epidemiological Review of a Re‐Emerging Infectious DiseaseClinical Infectious Diseases, 2009